https://agenebio.com/ 2026-10-09T20:25:30+00:00 https://agenebio.com/agenebio-received-us-patent/ 2015-01-05T19:31:23+00:00 https://agenebio.com/brain-overactivity-may-drive-disease-progress-in-alzheimers/ 2015-01-05T19:33:38+00:00 https://agenebio.com/quieting-memory-related-brain-structure-can-improve-memory-hyperactive-hippocampus-response-or-root-cause/ 2015-01-05T19:36:23+00:00 https://agenebio.com/drug-improves-brain-function-in-condition-that-leads-to-alzheimers/ 2015-01-05T19:37:24+00:00 https://agenebio.com/trial-shows-current-drug-slows-alzheimers-onset/ 2015-03-12T16:24:56+00:00 https://agenebio.com/agenebio-scouts-deals-and-dollars-ahead-of-alzheimers-phiii/ 2015-03-12T16:25:46+00:00 https://agenebio.com/agenebio-ceo-says-delays-in-alzheimers-onset-could-save-millions-as-paradigm-shifts/ 2015-03-12T16:26:21+00:00 https://agenebio.com/epilepsy-drug-may-reverse-memory-loss-of-potential-alzheimers-patients/ 2015-03-12T16:26:46+00:00 https://agenebio.com/a-drug-has-been-found-that-reverses-a-precursor-to-alzheimers/ 2015-03-12T16:27:00+00:00 https://agenebio.com/new-drug-approach-may-delay-alzheimers-dementia/ 2015-03-12T17:57:03+00:00 https://agenebio.com/levetiracetam-and-memory-function-epilepsy-drug-calms-the-hippocampus-aids-memory/ 2015-03-12T18:19:25+00:00 https://agenebio.com/new-approach-to-delay-alzheimers-dementia-onset-to-be-tested-in-phase-3-clinical-trial/ 2015-03-13T12:23:43+00:00 https://agenebio.com/drug-may-restore-brain-function-memory-in-patients-at-risk-for-alzheimers-disease/ 2015-03-13T12:25:18+00:00 https://agenebio.com/phase-3-trial-of-epilepsy-drug-for-cognitive-impairment-to-be-initiated/ 2015-03-13T12:28:24+00:00 https://agenebio.com/agenebios-agb101-enroute-to-phase-iii-on-back-of-amci-phase-ii/ 2015-03-17T14:25:02+00:00 https://agenebio.com/clinical-trial-reveals-promising-brain-therapeutic-drug-for-the-pre-dementia-stage-of-alzheimers-disease/ 2015-03-19T15:33:05+00:00 https://agenebio.com/could-epilepsy-drug-help-treat-alzheimers-disease/ 2015-03-19T15:34:54+00:00 https://agenebio.com/an-epilepsy-drug-to-prevent-cognitive-decline/ 2015-04-02T17:32:14+00:00 https://agenebio.com/podcast-promise-shown-in-different-approach-to-alzheimers/ 2015-04-30T14:21:53+00:00 https://agenebio.com/epilepsy-drug-to-treat-alzheimers-disease-progression/ 2015-07-16T16:03:58+00:00 https://agenebio.com/clinical-trials-on-alzheimers-disease-ctad/ 2015-08-04T14:45:07+00:00 https://agenebio.com/7th-annual-biotech-showcase-2015/ 2015-08-04T14:59:58+00:00 https://agenebio.com/hopkins-agenebio-to-launch-trial-of-alzheimers-drug-in-partnership-with-nih/ 2015-09-15T11:50:50+00:00 https://agenebio.com/nlh-awards-johns-hopkins-grant-to-clinically-test-drug-for-early-alzheimers/ 2015-09-15T13:42:08+00:00 https://agenebio.com/agenebios-hope4mci-phase-3-trial-receives-support-from-nih/ 2015-09-15T17:00:56+00:00 https://agenebio.com/nih-awards-7-5-million-grant-for-agenebio-hope4mci-phase-3-clinical-trial-to-delay-the-onset-of-alzheimers-dementia-2/ 2015-09-15T21:26:38+00:00 https://agenebio.com/jhu-team-gets-7-5-million-to-test-alzheimers-drug/ 2015-09-16T11:31:28+00:00 https://agenebio.com/baltimore-biopharm-gets-nih-grant/ 2015-09-16T11:31:55+00:00 https://agenebio.com/hopkins-agenebio-to-launch-trial-of-alzheimers-drug-in-partnership-with-nih-2/ 2015-09-16T14:22:56+00:00 https://agenebio.com/first-drug-to-prevent-alzheimers-gets-clinical-trial/ 2015-09-17T13:49:23+00:00 https://agenebio.com/this-jhu-startup-is-working-on-a-treatment-to-prevent-alzheimers/ 2015-09-17T13:54:09+00:00 https://agenebio.com/7-5-million-grant-awarded-to-start-clinical-trial-for-alzheimers/ 2015-09-17T14:44:47+00:00 https://agenebio.com/drug-for-early-alzheimers-heads-to-clinical-trial/ 2015-09-21T12:07:02+00:00 https://agenebio.com/new-alzheimer-trial-to-use-epilepsy-drug-that-calms-brain-activity/ 2015-09-22T11:29:12+00:00 https://agenebio.com/new-alzheimer-trial-will-use-epilepsy-drug/ 2015-09-22T11:30:12+00:00 https://agenebio.com/potential-alzheimers-drug-gets-funding-for-clinical-testing/ 2015-09-24T17:57:13+00:00 https://agenebio.com/bio-investor-forum/ 2015-10-06T12:08:35+00:00 https://agenebio.com/us-against-alzheimers-out-of-the-shadows-dinner/ 2015-10-06T13:29:49+00:00 https://agenebio.com/therapeutic-area-partnering-tap-conference/ 2015-11-12T17:44:24+00:00 https://agenebio.com/slow-down/ 2015-11-18T13:24:59+00:00 https://agenebio.com/future-of-innovation-in-medicine-conference-incentives-for-new-medical-treatments-and-global-health/ 2015-11-24T17:30:59+00:00 https://agenebio.com/from-truly-new-to-deja-vu-investigational-therapy-news-at-ctad/ 2015-11-25T14:01:03+00:00 https://agenebio.com/baltimore-biopharm-hires-neuroscience-veteran-mohs-vp/ 2015-12-08T17:02:26+00:00 https://agenebio.com/the-faces-of-alzheimers-part-iv-face-of-the-researcher-and-the-future/ 2015-12-21T14:24:39+00:00 https://agenebio.com/bio-ceo-investor-conference/ 2016-02-02T15:12:18+00:00 https://agenebio.com/neuroscience-biopartnering-investment-forum/ 2016-02-17T13:15:58+00:00 https://agenebio.com/17th-international-conference-alzheimers-drug-discovery/ 2016-09-14T20:07:32+00:00 https://agenebio.com/9th-international-conference-clinical-trials-alzheimers-disease/ 2016-12-15T14:33:13+00:00 https://agenebio.com/alzheimers-association-international-conference-aaic/ 2017-07-24T15:40:47+00:00 https://agenebio.com/agenebio-founder-michela-gallagher-speak-2018-nih-alzheimers-research-summit/ 2018-02-28T14:19:31+00:00 https://agenebio.com/agenebio-speak-asent-2018-annual-meeting/ 2018-02-28T14:47:06+00:00 https://agenebio.com/milken-global-conference-2018/ 2018-04-10T14:06:29+00:00 https://agenebio.com/doctors-discuss-alzheimers-advancements/ 2019-09-11T15:36:40+00:00 https://agenebio.com/agenebio-announces-additional-funding-to-advance-novel-gaba-a-therapeutic-program-to-address-alzheimers-and-other-cns-conditions/ 2021-07-08T22:00:01+00:00 https://agenebio.com/agenebio-announces-two-nih-grant-awards-to-advance-its-therapeutic-pipeline-to-combat-progression-of-alzheimers-disease/ 2021-07-08T22:05:30+00:00 https://agenebio.com/agenebio-believes-a-switch-in-research-strategy-can-make-alzheimers-preventable/ 2021-07-08T22:09:02+00:00 https://agenebio.com/agenebio-founder-dr-michela-gallagher-participates-2018-milken-global-conference/ 2021-07-08T22:14:39+00:00 https://agenebio.com/agenebio-inc-panel-participation-at-american-college-of-neuropsychopharmacology-meeting-acnp/ 2021-07-08T22:17:49+00:00 https://agenebio.com/agenebio-using-over-3m-in-new-funding-to-further-develop-alzheimers-drug/ 2021-07-08T22:28:55+00:00 https://agenebio.com/darryle-schoepp-ph-d-joins-the-agenebio-board-of-directors/ 2021-07-08T22:34:39+00:00 https://agenebio.com/founder-ceo-dr-michela-gallagher-featured-in-alzheimers-drug-discovery-foundation-video/ 2021-07-08T22:39:15+00:00 https://agenebio.com/hope4mci-trial-first-trial-targeting-reduction-of-hippocampal-overactivity-to-treat-mild-cognitive-impairment-due-to-alzheimers-disease-with-agb101/ 2021-07-08T22:40:31+00:00 https://agenebio.com/hope4mci-trial-targeting-reduction-of-hippocampal-overactivity-to-treat-mild-cognitive-impairment-due-to-alzheimers-disease-with-agb101/ 2021-07-08T22:53:36+00:00 https://agenebio.com/sharon-rosenzweig-lipson-agenebio-vp-of-research-and-development-presents-at-the-9th-annual-neurodegeneration-drug-development-summit/ 2021-07-08T22:55:28+00:00 https://agenebio.com/t-j-oshie-and-dr-michela-gallagher-honored-at-ninth-annual-great-ladies-luncheon/ 2021-07-08T22:58:04+00:00 https://agenebio.com/agenbio-longevity-innovations-and-neurodegeneration-showcase/ 2021-07-08T22:59:02+00:00 https://agenebio.com/agenebio-presents-at-biotech-showcase/ 2021-07-08T23:02:11+00:00 https://agenebio.com/american-society-experimental-neurotherapeutics-asent-20th-annual-meeting/ 2021-07-08T23:03:57+00:00 https://agenebio.com/2018-nih-alzheimers-research-summit/ 2021-07-08T23:14:38+00:00 https://agenebio.com/agenebio-present-neuroscience-biopartnering-investment-forum/ 2021-07-12T13:33:50+00:00 https://agenebio.com/new-hope4mci-phase-3-clinical-trial-website/ 2021-07-12T13:39:23+00:00 https://agenebio.com/vp-clinical-development-presents-at-2021-nih-alzheimer-disease-summit/ 2021-07-12T13:46:14+00:00 https://agenebio.com/completion-of-patient-enrollment-in-phase-2b-clinical-trial/ 2021-07-12T13:49:32+00:00 https://agenebio.com/patient-enrollment-in-phase-3-clinical-trial-to-evaluate-agb101/ 2021-07-12T13:50:33+00:00 https://agenebio.com/phase-2-clinical-trial-results-publication-for-new-approach-to-delaying-the-onset-of-alzheimers/ 2021-07-12T13:51:18+00:00 https://agenebio.com/agenebio-appoints-industry-leaders-patrick-lepore-as-chairman-of-the-board-and-jerry-mclaughlin-as-president-and-chief-executive-officer/ 2021-07-12T13:52:05+00:00 https://agenebio.com/agenebio-appoints-richard-mohs-phd-vice-president-clinical-development/ 2021-07-12T13:52:31+00:00 https://agenebio.com/agenebio-ceo-jerry-mclaughlin-to-present-at-biotech-showcase-2015/ 2021-07-12T13:53:54+00:00 https://agenebio.com/agenebio-founder-and-chief-scientific-officer-receives-society-for-neurosciences-mika-salpeter-lifetime-achievement-award/ 2021-07-12T13:54:28+00:00 https://agenebio.com/agenebio-founder-presents-alzheimers-association-international-conference/ 2021-07-12T13:54:54+00:00 https://agenebio.com/agenebio-present-bio-ceo-investor-conference/ 2021-07-12T13:55:35+00:00 https://agenebio.com/agenebio-presents-pharmacokinetic-profile-of-proprietary-extended-release-once-a-day-agb101-formulation-at-8th-clinical-trials-on-alzheimers-disease/ 2021-07-12T13:56:00+00:00 https://agenebio.com/agenebio-receive-10-million-nih-funding-advance-program-mild-cognitive-impairment-due-alzheimers-disease/ 2021-07-12T13:57:24+00:00 https://agenebio.com/agenebio-receives-grant-alzheimers-drug-discovery-foundation-drug-discovery-program-delay-onset-alzheimers-dementia/ 2021-07-12T13:57:55+00:00 https://agenebio.com/agenebio-receives-grant-from-alzheimers-drug-discovery-foundation-for-new-approach-to-delaying-the-onset-of-alzheimers-dementia/ 2021-07-12T13:58:27+00:00 https://agenebio.com/agenebio-receives-nih-grant-initiate-phase-3-hope4mci-trial-treat-mci-due-alzheimers-disease/ 2021-07-12T13:58:51+00:00 https://agenebio.com/agenebio-to-present-as-a-top-project-to-watch-most-licensable-products-in-neuroscience-at-therapeutic-area-partnership-conference/ 2021-07-12T13:59:24+00:00 https://agenebio.com/agenebio-to-present-at-8th-annual-clinical-trials-on-alzheimers-disease/ 2021-07-12T13:59:49+00:00 https://agenebio.com/agenebio-to-present-at-future-of-innovation-in-medicine-conference/ 2021-07-12T14:00:18+00:00 https://agenebio.com/nih-awards-7-5-million-grant-for-agenebio-hope4mci-phase-3-clinical-trial-to-delay-the-onset-of-alzheimers-dementia/ 2021-07-12T14:00:42+00:00 https://agenebio.com/agenebio-to-present-at-bio-investor-forum-2015/ 2021-07-12T14:01:08+00:00 https://agenebio.com/vice-president-research-development-presents-at-alzheimers-association-international-conference/ 2021-07-29T17:26:20+00:00 https://agenebio.com/agenebio-ceo-michela-gallagher-and-vice-president-of-research-and-development-sharon-rosenzweig-lipson-present-at-biomarkers-for-alzheimers-disease-2021/ 2021-09-02T18:04:29+00:00 https://agenebio.com/boosting-the-brains-brakes-to-beat-memory-loss/ 2021-12-15T15:02:28+00:00 https://agenebio.com/richard-mohs-agenebio-vice-president-of-clinical-development-presents-at-the-15th-annual-ctad-conference/ 2022-12-22T18:53:43+00:00 https://agenebio.com/agenebio-leadership-presents-at-american-society-for-experimental-neurotherapeutics-annual-meeting/ 2024-04-22T23:14:47+00:00 https://agenebio.com/agenebio-founder-michela-gallagher-presents-hope4mci-results-at-12th-alzheimers-parkinsons-drug-development-summit/ 2024-04-22T23:17:57+00:00 https://agenebio.com/agenebios-phase-2b-trial-shows-agb101-slows-progression-of-brain-atrophy-in-patients-with-mild-cognitive-impairment-due-to-alzheimers-disease-who-are-non-carriers-of-the-apoe-4-allel/ 2024-10-17T15:03:07+00:00 https://agenebio.com/medical-news-today-could-a-once-daily-pill-for-seizures-also-treat-alzheimers-disease/ 2024-10-29T17:46:58+00:00 https://agenebio.com/the-alzheimers-association-international-conference-aaic-toronto-july-27-31-2025/ 2025-08-05T15:13:03+00:00 https://agenebio.com/recent-report-that-levetiracetam-could-stop-the-plaque-formation-of-alzheimers-disease-in-its-earliest-stages-is-further-confirmation-of-the-positive-effects-of-agenebios-novel-thera/ 2026-02-17T13:47:26+00:00